23/06/2003

Scientists identify gene that can 'stop' ovarian cancer

Cancer Research UK scientists have claimed to have isolated a gene that has the power to stop ovarian cancer developing, according to a report published yesterday.

Researchers found that the gene, known as OPCML, was "switched off" in almost 90% of the ovarian tumours that were tested. And experiments in the laboratory have shown that when fully functioning OPCML genes are inserted into human ovarian cancer cells tumour growth is dramatically suppressed.

Dr Hani Gabra, who led the research at Cancer Research UK's Edinburgh oncology unit, said: "This is a very important discovery in identifying what seems to be a key tumour suppressor gene in ovarian cancer.

"We have found that these genes are frequently 'switched off' at very early stages of the disease and fail to make essential proteins. But when we switch these genes back on in the cancer cells tumours are suppressed.

In normal ovarian tissue, OPCML seems to prevent cells from being cancerous but defects in the gene may open the way for development of the disease.

Scientists believe it may be possible to devise drugs to mimic the effects of OPCML in order to block the growth of ovarian cancer cells.

Ovarian cancer has no obvious symptoms in the early stages and is particularly difficult to detect. There is no effective screening procedure that can indicate pre-cancerous cells as there is in cervical and bowel cancer.

Dr Grant Sellar, who also worked on the report, said: "This is an exciting development in our understanding of the early stages of ovarian cancer. Now we need to work on learning more about the function of OPCML and how it works in relation to ovarian cancer."

The lifetime risk for a woman in England or Wales developing ovarian cancer is 1 in 48. In the UK in 2000, there were 4,431 deaths from ovarian cancer – 3,909 in England and Wales, 442 in Scotland and 100 in Northern Ireland.

Five-year survival in England, Wales and Scotland is around 29%, and in Northern Ireland it is around 27%. Sweden has the best five-year survival rate in Europe at 45%.

(GMcG)

Related UK National News Stories
Click here for the latest headlines.

26 September 2003
Genetic testing could assist in cancer treatment, report claims
Testing tumours for the breast cancer gene BRCA1 could be a powerful way of predicting how patients will respond to chemotherapy, scientists from Breast Cancer Campaign and Cancer Research UK have said. Researchers have found that tumour cells react differently to chemotherapy depending on how well BRCA1 is working within them.
17 June 2005
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
01 June 2015
Scientists Discover Radiotherapy Improvements For Cancers
Scientists from Cancer Research UK have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
02 August 2004
Gene therapy trial for cancer patients gets green light
The green light has been given for a large clinical trial of a new gene therapy treatment for patients with Glioma - one of the most aggressive types of brain tumours for which there is currently no cure. The new gene therapy treatment involves injecting Herpes simplex virus into the brain tumours of Glioma patients.